IL6 and neoplasm: To date, some prognostic markers were investigated in advanced NSCLC, including positron emission tomography parameters, driver gene mutation, number of metastatic sites, interleukin-6, cell-free DNA, circulating tumor cells, inflammation parameters, and tumor-infiltrating lymphocytes (TILs) [6–16].